Bristol Myers Squibb is facing investment scrutiny as it utilizes a wholly owned subsidiary, while the acquisition of the AI startup Manus in Beijing is ordered to unwind.

The entities involved

• Manus →

  AI agent

  Nothing else this week.

• Bristol-Myers Squibb →

  American pharmaceutical company

  • Bristol-Myers Squibb is developing innovative treatments and supporting Cyprus' national effort in haematology.Mon 13:45
  • FDA gave tentative approval to Lupin for an alternative formulation of a Bristol-Myers Squibb drug, which Lupin plans to manufacture in Somerset.Mon 09:09
• Meta →

  American technology company

  • The enterprise platform launch is facing market share pressure, leading to Mark Zuckerberg defending Meta's strategic direction.Mon 17:55
  • Meta is launching a new commercial wing specifically focused on AI deployment.Mon 17:55

Related events

• Bristol-Myers Squibb holds exclusive commercial rights in Japan after the FDA accepted Zenas's Biologics License Application.Sep 23
• Bristol-Myers Squibb and Johnson & Johnson are both companies that are currently targets of LB Pharmaceuticals.Sep 9
• Cocrystal Pharma and Bristol-Myers Squibb are competing for investment as healthcare companies.Sun 22:20
• Financial Times reported ongoing deal talks between AstraZeneca and Bristol-Myers Squibb, potentially creating a pharmaceutical giant.Aug 3
• Major healthcare companies like BMS, J&J, and EL are facing market pressures, including biosimilar erosion, while maintaining strong sector positions.Aug 31